Datapoint: BMS, Nektar End $2B Partnership

May 5

Bristol Myers Squibb and Nektar Therapeutics are scrapping their $2 billion partnership. The companies were testing combinations of Opdivo and bempegaldesleukin, an experimental Nektar drug designed to stimulate interleukins. The combo showed poor results in melanoma, renal cell carcinoma and urothelial cancer. For the treatment of urothelial cancer, Opdivo currently holds covered or better status for 67% of all insured lives under the pharmacy benefit. Under the medical benefit, 88% of lives have covered or better access to Opdivo.

SOURCE: MMIT Analytics, as of 4/19/22